Targeting emerging Mycobacterium avium infections: perspectives into pathways and antimicrobials for future interventions

Future Microbiol. 2021 Jul:16:753-764. doi: 10.2217/fmb-2021-0016. Epub 2021 Jul 6.

Abstract

Mycobacterium avium is an emerging opportunistic pathogen, globally. Infections caused by M. avium are laborious to treat and could result in drug resistance. This review discusses the importance of many factors including the cell wall in M. avium pathogenesis, since this unique structure modulates the pathogen's ability to thrive in various hosts and environmental niches including conferring resistance to killing by antimicrobials. More research efforts in future are solicited to develop novel therapeutics targeting M. avium. The complete eradication of M. avium infection in immunocompromised individuals would need a deeper understanding of the source of infection, unique underlying mechanisms and its uncharacterized pathways. This could, perhaps in future, hold the key to target and treat M. avium more effectively.

Keywords: Mycobacterium avium; antimicrobial resistance; cell wall; efflux pumps; β lactamase; β lactams.

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents* / pharmacology
  • Cell Wall
  • Humans
  • Mycobacterium avium / drug effects
  • Mycobacterium avium-intracellulare Infection* / drug therapy

Substances

  • Anti-Infective Agents